Latest Industry Insights

One of the COVID-19 vaccine candidates that received fast track designation by the FDA is mRNA-1273, developed by Moderna, a clinical stage biotechnology company. The company has shared the positive interim results from a Phase I clinical trial of the vaccine in The New England Journal of Medicine .

We spoke to Ari Goldfarb, CEO of Kando, about how their wastewater monitoring technology works and how it is being applied to the current monitoring efforts in the COVID-19 pandemic.

Technology Networks spoke with Rohan Thakur, Executive Vice President of Life Sciences Mass Spectrometry at Bruker Daltonics, to discuss the company's latest analytical technologies and their capabilities.

When the COVID-19 global pandemic was declared in March, Twist Biopharma decided to utilize its synthetic antibody discovery libraries to discover antibodies that could have diagnostic or treatment capabilities. Technology Networks spoke with Aaron Sato, Chief Scientific Officer, Twist Biopharma, to find out more.

The Innovative Genomics Institute (IGI) has launched an impressive COVID-19 diagnostic testing laboratory at UC Berkeley. Technology Networks spoke with Professor Jennifer Doudna, Executive Director at IGI and Professor of Molecular and Cell Biology and Chemistry at the University of California, Berkeley, to learn exactly how this ambitious effort has been achieved.

The World Health Organization recognizes that, as of June 22, there are over 140 vaccines against COVID-19 in various stages of development. 13 of those candidates are now in human clinical trials. In this insights piece, we explore what those candidates are, and who is developing them.

With advances in cellular and tissue-based imaging, researchers are able to peel back the layers on new challenges and test hypotheses to solve more problems. We heard about some of the advancements being made in the field of confocal microscopy.

In this article, we take a closer look at the use of lung and airway organoids for drug and vaccine development and explore how they are being used to study infectivity in human respiratory diseases, such as COVID-19.

With the first clinical trial of CRISPR gene editing in progress and the controversy of the first gene-edited babies continuing to spark discussion, it is more important than ever to better understand not only the benefits but also the risks of CRISPR-based therapies.

In a study published in Cell Reports, members of the Washburn Lab described their three-pronged approach to analyzing protein complexes – affinity tag protein purification, chemical crosslinking with high-resolution mass spectrometry and computational molecular modeling with protein docking. We interviewed Washburn to find out more.